Fate Therapeutics

Related records

Trials (25)

• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
• A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
• A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
• A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
• First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
• FT516 in Subjects With Advanced Hematologic Malignancies
• FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
• FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
• FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
• FT538 in Subjects With Advanced Hematologic Malignancies
• FT576 in Subjects With Multiple Myeloma
• FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
• FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
• FT819 in Subjects With B-cell Malignancies
• FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
• FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
• Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy